login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
GAIN THERAPEUTICS INC (GANX) Stock News
USA
-
Nasdaq
- NASDAQ:GANX -
US36269B1052
-
Common Stock
4.0504
USD
+0 (+0.01%)
Last: 12/10/2025, 10:33:19 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
GANX Latest News, Press Relases and Analysis
All
Press Releases
2 days ago - By: Zacks Investment Research
Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy
20 days ago - By: Gain Therapeutics, Inc.
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
23 days ago - By: Zacks Investment Research
Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know
a month ago - By: Gain Therapeutics, Inc.
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update
a month ago - By: Gain Therapeutics, Inc.
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update
a month ago - By: Gain Therapeutics, Inc.
Gain Therapeutics to Present at Neuroscience 2025
2 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
2 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
2 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
2 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
2 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®
2 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®
3 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
3 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
3 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease
3 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease
3 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation
4 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update
4 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update
4 months ago - By: Benzinga
- Mentions:
XTLB
ASMB
MCRB
SNES
...
12 Health Care Stocks Moving In Friday's After-Market Session
5 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference
5 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference
5 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering
5 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering
5 months ago - By: Benzinga
- Mentions:
CYCC
LIXT
CBIO
RPTX
...
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
5 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics Announces Proposed Public Offering
5 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics Announces Proposed Public Offering
5 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
5 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
6 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics to Participate in Upcoming Investor Conferences
7 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
7 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
7 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update
7 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update
7 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
7 months ago - By: Gain Therapeutics, Inc.
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
Please enable JavaScript to continue using this application.